+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Tenosynovitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 137 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5970336
The 7 major tenosynovitis markets are expected to exhibit a CAGR of 4.25% during 2023-2034.

The tenosynovitis market has been comprehensively analyzed in this report titled "Tenosynovitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tenosynovitis refers to a medical condition characterized by the inflammation of the protective sheath surrounding a tendon, known as the synovium. Tendons are essential for connecting muscles to bones, facilitating movement. Inflammation of the synovium can lead to pain, swelling, and limited joint mobility. Common symptoms of tenosynovitis include localized tenderness, warmth, and stiffness in the affected area, often exacerbated by movement or pressure. The condition most commonly affects the fingers, wrists, hands, and feet, but it can occur in any tendon sheath throughout the body. Diagnosing this ailment typically involves a thorough medical history review and physical examination, focusing on the affected area's tenderness, swelling, and range of motion. Physicians may also utilize imaging techniques, like ultrasound or magnetic resonance imaging (MRI), to visualize the inflamed tendon sheath and rule out various other potential causes of the symptoms. Laboratory tests, such as blood workups, may further help to identify any underlying inflammatory conditions contributing to tenosynovitis.

The escalating cases of direct trauma or injury to a tendon due to sudden impact, twisting, or excessive force, resulting in inflammation of the synovium, are primarily driving the tenosynovitis market. In addition to this, the inflating utilization of effective treatments, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroid injections, immobilization techniques, etc., to alleviate symptoms and hinder further deterioration of the condition is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies, on account of their several benefits like enhancing muscle strength, refining coordination, and augmenting overall motor skills in individuals suffering from the illness, is also bolstering the market growth. Apart from this, the rising usage of minimally invasive procedures, such as ultrasound-guided tenosynovial debridement methods, since they aim at precisely addressing inflamed tendon sheaths and restoring joint function while reducing the risk of damaging adjacent structures, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of regenerative medicine approaches, encompassing platelet-rich plasma (PRP) injections and stem cell therapies, which aid in tissue repair and alleviation of symptoms by harnessing the body's natural healing mechanisms, is expected to drive the tenosynovitis market during the forecast period.

This report provides an exhaustive analysis of the tenosynovitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tenosynovitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tenosynovitis market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the tenosynovitis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the tenosynovitis market

Competitive Landscape:

This report also provides a detailed analysis of the current tenosynovitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

  • How has the tenosynovitis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the tenosynovitis market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the tenosynovitis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of tenosynovitis across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of tenosynovitis by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of tenosynovitis by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with tenosynovitis across the seven major markets?
  • What is the size of the tenosynovitis patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of tenosynovitis?
  • What will be the growth rate of patients across the seven major markets?

Tenosynovitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for tenosynovitis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tenosynovitis market?
  • What are the key regulatory events related to the tenosynovitis market?
  • What is the structure of clinical trial landscape by status related to the tenosynovitis market?
  • What is the structure of clinical trial landscape by phase related to the tenosynovitis market?
  • What is the structure of clinical trial landscape by route of administration related to the tenosynovitis market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

?1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Tenosynovitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Tenosynovitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Tenosynovitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Tenosynovitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Tenosynovitis - Unmet Needs10 Tenosynovitis - Key Endpoints of Treatment
11 Tenosynovitis - Marketed Products
11.1 List of Tenosynovitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Tenosynovitis - Pipeline Drugs
12.1 List of Tenosynovitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 Tenosynovitis - Attribute Analysis of Key Marketed and Pipeline Drugs
14 Tenosynovitis - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Tenosynovitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tenosynovitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Tenosynovitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Tenosynovitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Tenosynovitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Tenosynovitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tenosynovitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Tenosynovitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Tenosynovitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tenosynovitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Tenosynovitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Tenosynovitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tenosynovitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Tenosynovitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Tenosynovitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tenosynovitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Tenosynovitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Tenosynovitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tenosynovitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Tenosynovitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Tenosynovitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tenosynovitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Tenosynovitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Tenosynovitis - Access and Reimbursement Overview
16 Tenosynovitis - Recent Events and Inputs From Key Opinion Leaders
17 Tenosynovitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Tenosynovitis Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...